COLL Collegium Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COLL

Price (delayed)

$22.45

Market cap

$730.87M

P/E Ratio

14.77

Dividend/share

N/A

EPS

$1.52

Enterprise value

$1.68B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 85
Relative Profitability: Rel. Profitability: 83

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts.

Highlights
The equity is up by 34% year-on-year
COLL's P/E is 25% below its last 4 quarters average of 20.0
Collegium Pharmaceutical's EPS has decreased by 36% from the previous quarter but it has increased by 33% YoY
The net income has contracted by 36% from the previous quarter but it has grown by 32% YoY
The quick ratio has dropped by 52% since the previous quarter and by 24% year-on-year
COLL's debt is up by 36% since the previous quarter and by 32% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.collegiumpharma.com
Peers: UTHR LPCN SUPN

Key stats

What are the main financial stats of COLL

COLL stock price

How has the Collegium Pharmaceutical stock price performed over time
Intraday
-1.45%
1 week
1.17%
1 month
-17.19%
1 year
-35.67%
YTD
-51.51%
QTD
-37.98%

Financial performance

How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$808.21M
Gross profit
$485.09M
Operating income
$157.4M
Net income
$47.92M
Gross margin
60%
Net margin
5.9%
COLL's net margin is down by 37% since the previous quarter but it is up by 16% year-on-year
The net income has contracted by 36% from the previous quarter but it has grown by 32% YoY
Collegium Pharmaceutical's operating income has increased by 25% YoY but it has decreased by 16% QoQ
Collegium Pharmaceutical's gross profit has increased by 21% YoY

Price vs fundamentals

How does COLL's price correlate with its fundamentals

Growth

What is Collegium Pharmaceutical's growth rate over time

Valuation

What is Collegium Pharmaceutical stock price valuation
COLL P/E details
P/E
14.77
P/B
2.33
P/S
0.9
EV/EBIT
10.88
EV/EBITDA
10.59
EV/Sales
2.07
Collegium Pharmaceutical's EPS has decreased by 36% from the previous quarter but it has increased by 33% YoY
COLL's P/E is 25% below its last 4 quarters average of 20.0
The price to book (P/B) is 41% lower than the 5-year quarterly average of 4.0 and 41% lower than the last 4 quarters average of 4.0
The equity is up by 34% year-on-year
COLL's price to sales (P/S) is 46% lower than its 5-year quarterly average of 1.7 and 39% lower than its last 4 quarters average of 1.5
The revenue is up by 14% year-on-year

Efficiency

How efficient is Collegium Pharmaceutical business performance
The company's return on assets fell by 41% QoQ but it rose by 23% YoY
The ROE is down by 40% QoQ but it is up by 2.6% YoY
The ROIC has contracted by 22% from the previous quarter
Collegium Pharmaceutical's ROS has decreased by 18% from the previous quarter

Dividends

What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COLL.

Financial health

How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 17% more than its total liabilities
The quick ratio has dropped by 52% since the previous quarter and by 24% year-on-year
The current ratio has declined by 40% since the previous quarter and by 13% year-on-year
COLL's debt is up by 36% since the previous quarter and by 32% year-on-year
The debt to equity rose by 36% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.